Human Recombinant CDC7 & DBF4, Active protein, GST Tag (V2LY-0526-LY3002)

Vaca, G., Martinez‐Gonzalez, L., Fernandez, A., Rojas‐Prats, E., Porras, G., Cuevas, E. P., ... & Martin‐Requero, Á. (2021). Therapeutic potential of novel Cell Division Cycle Kinase 7 inhibitors on TDP‐43‐related pathogenesis such as Frontotemporal Lobar Degeneration (FTLD) and amyotrophic lateral sclerosis (ALS). Journal of Neurochemistry, 156(3), 379-390.

Rojas-Prats, E., Martinez-Gonzalez, L., Gonzalo-Consuegra, C., Liachko, N. F., Perez, C., Ramírez, D., ... & Martinez, A. (2021). Targeting nuclear protein TDP-43 by cell division cycle kinase 7 inhibitors: A new therapeutic approach for amyotrophic lateral sclerosis. European Journal of Medicinal Chemistry, 210, 112968.

Iwai, K., Nambu, T., Kashima, Y., Yu, J., Eng, K., Miyamoto, K., ... & Ohashi, A. (2021). A CDC7 inhibitor sensitizes DNA-damaging chemotherapies by suppressing homologous recombination repair to delay DNA damage recovery. Science Advances, 7(21), eabf0197.

Ma, Q., Zhang, J., Zhang, M., Lan, H., Yang, Q., Li, C., & Zeng, L. (2020). MicroRNA-29b targeting of cell division cycle 7-related protein kinase (CDC7) regulated vascular smooth muscle cell (VSMC) proliferation and migration. Annals of Translational Medicine, 8(22).

Jaafari-Ashkavandi, Z., Ashraf, M. J., & Abbaspoorfard, A. A. (2019). Overexpression of CDC7 in malignant salivary gland tumors correlates with tumor differentiation☆. Brazilian journal of otorhinolaryngology, 85, 144-149.

Gad, S. A., Ali, H. E., Gaballa, R., Abdelsalam, R. M., Zerfaoui, M., Ali, H. I., ... & Abd Elmageed, Z. Y. (2019). Targeting CDC7 sensitizes resistance melanoma cells to BRAF V600E-specific inhibitor by blocking the CDC7/MCM2-7 pathway. Scientific reports, 9(1), 1-12.

Shimizu, T., Doi, T., Kondo, S., Takahashi, H., Yamamoto, N., Sheldon-Waniga, E., ... & Kuboki, Y. (2018). First-in-human phase 1 study of TAK-931, an oral cell division cycle 7 (CDC7) inhibitor, in patients (pts) with advanced solid tumors.

Jin, S., Ma, H., Yang, W., Ju, H., Wang, L., & Zhang, Z. (2018). Cell division cycle 7 is a potential therapeutic target in oral squamous cell carcinoma and is regulated by E2F1. Journal of Molecular Medicine, 96(6), 513-525.

Li, X., Qian, X., Jiang, H., Xia, Y., Zheng, Y., Li, J., ... & Lu, Z. (2018). Nuclear PGK1 alleviates ADP-dependent inhibition of CDC7 to promote DNA replication. Molecular cell, 72(4), 650-660.

Locuson, C., Patel, M., Ohashi, A., Iwai, K., Nambu, T., Takeuchi, T., ... & Xia, C. (2017). Translational pharmacokinetic-pharmacodynamic xenograft model for TAK-931, a small molecule cell division cycle 7 (CDC7) kinase inhibitor.

Please try the standard protocols which include: protocols, troubleshooting and guide.

Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme Linked Immunospot (ELISpot)
Proteogenomic
Other Protocols